JonesResearch initiated coverage of Dyne Therapeutics (DYN) with a Buy rating and $30 price target Over the next 12 months, Dyne has two shots on goal in rare neuromuscular diseases, the analyst tells investors in a research note. The firm says the company’s “competitive edge” is the Force platform, which increases muscle delivery using an antibody fragment. It forecasts $3B in unadjusted worldwide peak sales in 2034.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics initiated with a Market Perform at Bernstein
- Dyne Therapeutics price target lowered to $32 from $46 at Baird
- Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating
- Dyne Therapeutics’ DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials
- Dyne having vHOT as primary endpoint ‘encouraging,’ says H.C. Wainwright